Simple research view

JNJ · Johnson & Johnson

$266.35 -0.27% Sep 10 close

Detected setup Trend Only · Setup Score 77/100

Stand aside — setup invalidated

Setup score 77, but distribution days reach 5 or more — stand aside until the condition resets.

2 independent risk warnings also present. Review before relying on the bullish setup.

Ask about JNJ

Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.

$JNJ

Johnson & Johnson

Johnson & Johnson is a mega-cap Pharmaceuticals: Major company in the Health Technology sector with a market cap of $642B.

Health Technology Pharmaceuticals: Major stock Stage 2 · Advancing Base 1

$266.35 latest close

⚠ Risk Signals

Rising Wedge prior_advance=27.3%, converging=yes, narrowing=24%, touches=upper:3/lower:3, trigger=broke

Bearish RSI Divergence Price higher high ($267.24→$273.41) but RSI lower high (72→69) — momentum diverging

Bearish structure on the daily chart — a heads-up for anyone holding, not a short signal. Does not affect the bullish setup score.

Join to Watchlist $JNJ Share card

Verdict · setup score 77/100 · data Sep 10 close · 1 session old

Stand aside — setup invalidated

Setup score 77, but distribution days reach 5 or more — stand aside until the condition resets.

Review six verdicts Inspect chart

Earnings

Normal technical setup

Next earnings Tuesday, October 13, 2026 Report time not confirmed by the source

Deterministic evidence

JNJ-0.27%

Broad market · SPY-0.60%

Same completed session window ending 2026-09-10. +0.33 points vs SPY.

Session internals Weak

Rule: closed flat-to-down and in the bottom third of the range. Judged on internals, not on the size of the move.

Vs prior close-0.27% From the open-1.43% Range position11% GapNo gap

QQQ confirmationConfirming (-1.06%) SMH confirmationConfirming (-2.44%)

Price bars, sourced event fields, and benchmark math only. This can adjust displayed short-term conviction; it does not change the stored scanner score or readiness.

Ask a Legend to interpret this evidence → Commentary only — never scanner evidence or a sizing recommendation.

Price $266.35 -0.3% Sep 10 close

52W High $281.07 5.2% below high

Wks Since High 0w 1w today

Base Depth 4.3% 5.5% today

RS Rank 57 percentile of scan

SMA 50 $262.48

Avg Vol 7,137,167

Rel Vol (Sep 10) 0.69×

More stats

52W Low $173.33

Tight Wks 1

Base B1

SMA 200 $236.81

RS Line vs High -8.4%

RS Line Slope +4.3% ▲

Group Rank #27/58

ADR% 1.7%

ATR(14) $5.29 (2.0%)

Vol Pace (live) N/A

U/D Vol 1.06

A/D Days 22A / 15D

A/D Rating A+

VDU Bars 0/10 d

Earnings in 31d

Position in 52-week range 86thpercentile of the 52-week range

$173.33low

$281.07high

JNJ Chart

Interactive price, volume, RS, RSI, and MACD charts are available after sign in.

Create a free account to load the full interactive chart for JNJ.

Create Free Account

Technical Analysis Report Card

$JNJ · $266.35 · as of 2026-09-10 · multi-factor read

/ 100

Technicals 75/100

Reference read from price & volume only — the verdict at the top of the page decides the action.

Trend · Daily / Weekly / Monthly

Daily ▬ Sideways / consolidating

Weekly ▲ Uptrend

Monthly ▲ Uptrend

Moving Averages

50-day$262.48 ↑

100-day$247.00 ↑

200-day$236.81 ↑

Bullish (50 > 200)

RSI (14)

Reading49.5 · Neutral

Neutral — momentum is balanced between buyers and sellers.

MACD (12/26/9)

StateWeakening

Histogram-0.875

Weakening — MACD slipped below its signal line. Histogram contracting.

Bollinger Bands (20,2)

%B / Width35% · 7.1%

Mid-band — no directional band edge in play.

Volume · Buyer vs Seller

Up/Down vol1.06 · Neutral

Rel volume0.69×

Balanced — up/down volume is roughly even; no clear hand. Recent volume is easing versus its baseline.

Support & Resistance

R · $269.43swing level

R · $275.69swing level

R · $281.0752-week high

Price · $266.35now

S · $263.83swing level

S · $250.44swing level

S · $245.49swing level

Fibonacci · Uptrend swing

23.6% ◄ price here$266.74

38.2%$257.88

50.0%$250.72

61.8%$243.56

78.6%$233.36

Retracement support zones measured from the recent swing low up to the high.

The verdict is free. The trade plan is Pro.

Unlock the exact entry, stop-loss, profit target, and reward-to-risk for JNJ — plus the full 500+ symbol scanner and Ask-the-Legends chat.

Start your 7-day free trial →

Weekly uptrendMonthly uptrendAbove 200-day MA50/200 bullish

Want this read in a legend's voice? Ask a Legend about JNJ

Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →

Legend Verdicts 6 methodology checks

Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.

Council consensus: 5 of 6 legends are Watching — building, not yet a confirmed buy.

Minervini

Watch

Minervini C

Trend-template read: 6/10 pass; wait for the soft misses to improve.

Passing evidence

1.1 Price > 150-day MA AND 200-day MAPrice $266.35, MA150 $245.11, MA200 $236.81

1.2 150-day MA > 200-day MAMA150 $245.11 vs MA200 $236.81

Failing evidence

1.8 RS rank ≥ 70 (prefer ≥ 85)RS rank 65

2. Quarterly EPS growth ≥ 25%From SEPA scan

6/10 checks

Method → Playbook → Ask →

O'Neil

Avoid

O'Neil D

CANSLIM read: fails C: Quarterly EPS acceleration ≥ 25%.

Passing evidence

N: Near 52-week high or RS line new high5.2% below high | RS line new high: False

S: Base tightness (ATR% ≤ 4.5%)ATR% 1.99%

Failing evidence

L: RS rank ≥ 80 (IBD leadership)RS rank 65

C: Quarterly EPS acceleration ≥ 25%Data unavailable

2/8 checks

Method → Playbook → Ask →

Weinstein

Watch

Weinstein B

Stage-analysis read: Stage 2 is present; 1 supporting checks need improvement.

Passing evidence

Stage 2 (Advancing phase) confirmedStage 2 (Advancing)

Price above 30-week MA (200-day proxy)Price $266.35 vs MA200 $236.81

Failing evidence

Volume expansion above averageVolume ratio 0.69x

6/7 checks

Method → Playbook → Ask →

Livermore

Watch

Livermore B

Pivotal-point read: constructive evidence is present, but relative strength is unresolved.

Passing evidence

Price$266.35

Distance from 52-week high5.2% below high

Failing evidence

Relative strengthRS 65

Volume vs average0.69x

3/6 checks

Method → Playbook → Ask →

Darvas

Watch

Darvas B

Box-theory read: constructive evidence is present, but relative strength is unresolved.

Passing evidence

Price$266.35

Distance from 52-week high5.2% below high

Failing evidence

Relative strengthRS 65

Volume vs average0.69x

3/6 checks

Method → Playbook → Ask →

Wyckoff

Watch

Wyckoff B

Supply-and-demand read: constructive evidence is present, but relative strength is unresolved.

Passing evidence

Price$266.35

Distance from 52-week high5.2% below high

Failing evidence

Relative strengthRS 65

Volume vs average0.69x

3/6 checks

Method → Playbook → Ask →

Base & Breakout

Breakout follow-through

No active breakout tracked — Legend AI monitors daily for pivot-point breaks. What's a breakout?

Unlock Base & Breakout Tracking

RS Line vs SPY 52-week relative strength · blue = RS line · dashed = MA50 · dot = NH ▲ Rising

Accumulation / Distribution last 65 sessions · green = acc on high vol · red = dist on high vol Net +1 A+

Minervini · Grade Card

Fundamentals & leadership quality — Minervini’s published criteria · 2/7 met

C 2/7 criteria

Separate score from the Minervini Trend Template (7/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.

✗ EPS acceleration ≥25% QoQ —

✗ Revenue growth ≥20% YoY +6%

✗ Gross margin ≥30% —

✗ ROE ≥17% —

✗ RS rating ≥80 (leadership) 65

✓ Stage 2 uptrend (Weinstein) Stage 2

✓ Within 25% of 52W high -5.2%

Method Playbook

Trade it like Weinstein EXACT LEVELS · PRO

Minervini O'Neil Livermore Weinstein Darvas Wyckoff

Weinstein B · Watch — The deterministic methodology check is Watch; wait for the failing or incomplete criteria to improve before the trigger can qualify.

Pivot

Pro level

Published-method rule: Use Stage 1 resistance and the rising 30-week moving average as the Stage 2 transition boundary.
Evidence: Canonical setup geometry is available with Pro.

Entry trigger

Pro level

Published-method rule: Require a Stage 2 breakout above resistance on expanding volume; avoid entries while the 30-week average is flat or falling.
Evidence: Canonical setup geometry is available with Pro.

Initial stop

Pro level

Published-method rule: Start below the breakout structure or Stage 1 support where a return to the base invalidates the Stage 2 transition.
Evidence: Canonical setup geometry is available with Pro.

Trail

Rule-based

Published-method rule: Trail beneath rising 30-week support or later higher swing lows while Stage 2 remains intact.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.

Exit / invalidation

Pro level

Published-method rule: Exit on a decisive 30-week support failure or a Stage 3/Stage 4 transition; never treat a failed Stage 2 break as healthy consolidation.
Evidence: Canonical setup geometry is available with Pro.

Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →

The published-method workflow is public. Unlock exact pivot, entry, stop, target, and sizing with Pro →

Pattern Analysis

Trend Only

77 setup score

RS Score 65

Trend template 7/8

Why This Setup? D+W Confluence

Trend Only · schematic

Gatekeeper 7/8 | Strong trend (7/8) | Good RS (65) | Stage 2

The Universal Edge Check · context only

What the setup still has going for it, recorded for later. The verdict above stands — these principles do not overrule it.

2/7 universals met

A relative-strength leader — not met RS rank 57 — laggard
Risk is defined — not met No stop — undefined risk
Asymmetric reward — partly met No target set
Not chasing (in range) — partly met Pivot distance unknown
Volume confirms — partly met 0.7× average — light
Clear of earnings — met in 31 days
In a confirmed uptrend — met Stage 2 · Trend template 7/8

Why these seven? → The Universal Edge

Minervini Trend Template

7/8

Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.

Price above SMA 150 & 200 $266.35 vs SMA150 $245.11 / SMA200 $236.81

SMA 150 above SMA 200 SMA150 $245.11 vs SMA200 $236.81

SMA 200 trending up Slope +7.74 over 20 days

SMA 50 above SMA 150 & 200 SMA50 $262.48

Price above SMA 50 $266.35 vs SMA50 $262.48

30%+ above 52-week low +53.7% from $173.33

Within 25% of 52-week high -5.2% from $281.07

RS score above 70 RS 65

Fundamentals

52W Range

86%

Mkt Cap SEC

641.9B

Rev YoY

+6%

EPS TTM

$11.03

P/E TTM

24.1x

Float

2.4B

Company

Company profile

Johnson & Johnson

JNJ · NYSE · Health Technology · Pharmaceuticals: Major

Weekly Context

Multi-timeframe signals from weekly bars

W. Trend

8/8

W. RS

W. Support

$220.37

W. Resist

$281.07

W. Patterns

Base Breakout

Weekly Structure

Trend Neutral

Tight Weeks 1

Confirmation Neutral

Scan History

20× streak

Sep 11

Trend Only ✓ Gate

Sep 11

Trend Only ✓ Gate

Sep 10

Trend Only ✓ Gate

78 0.0%

Sep 10

Trend Only ✓ Gate

78 0.0%

Sep 10

Trend Only ✓ Gate

77 0.0%

Sep 10

Trend Only ✓ Gate

77 0.0%

Get the full picture on JNJ

Pro members see entry/stop/target levels, R:R ratios, intraday alerts, and every setup detected across 500+ symbols daily.

Start 7-Day Free Trial